Maximov V - Search Results

1

miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells.

Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S, Volinia S, Jones KB, Croce CM, Aqeilan RI. Salah Z, et al. Among authors: maximov v. Oncotarget. 2015 Mar 10;6(7):4920-35. doi: 10.18632/oncotarget.3025. Oncotarget. 2015. PMID: 25749032 Free PMC article.

2

Genetic factors conferring metastasis in osteosarcoma.

Maximov VV, Aqeilan RI. Maximov VV, et al. Future Oncol. 2016 Jul;12(13):1623-44. doi: 10.2217/fon-2016-0014. Epub 2016 Apr 13. Future Oncol. 2016. PMID: 27072870

3

MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma.

Maximov VV, Akkawi R, Khawaled S, Salah Z, Jaber L, Barhoum A, Or O, Galasso M, Kurek KC, Yavin E, Aqeilan RI. Maximov VV, et al. Int J Cancer. 2019 Dec 1;145(11):3052-3063. doi: 10.1002/ijc.32368. Epub 2019 May 9. Int J Cancer. 2019. PMID: 31018244 Free article.

4

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.

Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. Pekarsky Y, et al. Among authors: maximov v. Cancer Res. 2006 Dec 15;66(24):11590-3. doi: 10.1158/0008-5472.CAN-06-3613. Cancer Res. 2006. PMID: 17178851

5

Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activity.

Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Palamarchuk A, et al. Among authors: maximov v. Cancer Res. 2005 Jun 1;65(11):4515-9. doi: 10.1158/0008-5472.CAN-05-0751. Cancer Res. 2005. PMID: 15930267

6

Akt phosphorylates and regulates Pdcd4 tumor suppressor protein.

Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Palamarchuk A, et al. Among authors: maximov v. Cancer Res. 2005 Dec 15;65(24):11282-6. doi: 10.1158/0008-5472.CAN-05-3469. Cancer Res. 2005. PMID: 16357133

7

Tal1 transgenic expression reveals absence of B lymphocytes.

Palamarchuk A, Zanesi N, Aqeilan RI, Efanov A, Maximov V, Santanam U, Hagan JP, Croce CM, Pekarsky Y. Palamarchuk A, et al. Among authors: maximov v. Cancer Res. 2006 Jun 15;66(12):6014-7. doi: 10.1158/0008-5472.CAN-06-0937. Cancer Res. 2006. PMID: 16778172

8

Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.

Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM. Pekarsky Y, et al. Among authors: maximov v. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19643-8. doi: 10.1073/pnas.0810965105. Epub 2008 Dec 8. Proc Natl Acad Sci U S A. 2008. PMID: 19064921 Free PMC article.

9

Mitochondrial 16S rRNA gene encodes a functional peptide, a potential drug for Alzheimer's disease and target for cancer therapy.

Maximov V, Martynenko A, Hunsmann G, Tarantul V. Maximov V, et al. Med Hypotheses. 2002 Dec;59(6):670-3. doi: 10.1016/s0306-9877(02)00223-2. Med Hypotheses. 2002. PMID: 12445508

10

Humanin binds MPP8: mapping interaction sites of the peptide and protein.

Maximov VV, Martynenko AV, Arman IP, Tarantul VZ. Maximov VV, et al. J Pept Sci. 2013 May;19(5):301-7. doi: 10.1002/psc.2500. Epub 2013 Mar 27. J Pept Sci. 2013. PMID: 23532874

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page